June 22nd, 2016 Natixis Partners advised The Carlyle Group for the disposal of Marle to IK Investment Partners
Natixis Partners advised The Carlyle Group for the disposal of a majority stake in Marle International SAS (“Marle” or “the Company”), to IK Investment Partners, an independent implant contract manufacturing company in Europe. Carlyle’s Europe Technology fund, majority shareholder since 2009, reinvested alongside management and the Marle family.
Established over 30 years ago as a family business, Marle has become a major company in the orthopaedic industry. The Company provides specialised manufacturing services for the production of a wide range of hip, knee, shoulder, spine and extremities implants as well as orthopaedic instruments of the highest quality. Covering the full scope of the manufacturing value chain and benefiting from remarkable R&D capabilities, the Company acts as a strategic partner to medical technology companies worldwide and delivers over 1 million products annually. Marle serves orthopaedic implant OEMs across Europe, the US, Latin America, Russia, Japan, Korea and China. Headquartered in Nogent (France), Marle runs six certified production sites in France and generated revenues of €82 million in 2015.
Under Carlyle’s ownership, the Company has demonstrated sustained organic growth resulting from sizeable investments in the production process and has enlarged its span of technologies and products through the acquisitions of several sites in France, including SEEP, ATS and Sferic in 2011, as well as Finortho in 2015.
Debt financing was provided by Capzanine.‹ Back to news